Skip to main content
AAN.com

Abstract

To examine the validity of criteria-based (clinical) diagnosis of Alzheimer's disease (AD), 4 physicians experienced in the evaluation of dementia patients applied 3 sets of diagnostic criteria to each of 62 patients based on standardized medical record information. Diagnostic outcome was validated by neuropathologic examination (completed previously) for all (43) demented patients and 4 nondemented patients and by follow-up in the remainder (15) with no dementia. Raters were blind to the composition of the study group as well as to the clinical and pathologic diagnoses. We evaluated 3 diagnostic criteria sets for AD: the American Psychiatric Association diagnostic criteria from the Diagnostic and Statistical Manual (DSM-III), the NINCDS-ADRDA Work Group criteria for the diagnosis of Alzheimer's disease (NINCDS), and the Eisdorfer and Cohen research diagnostic criteria for primary neuronal degeneration (ECRDC). ECRDC had the highest specificity (0.88) but also the greatest odds of false-negative diagnosis (LRneg = 0.61, sensitivity = 0.46). NINCDS had the best sensitivity (0.92, specificity = 0.651, and DSM-III showed intermediate values (sensitivity = 0.76, specificity = 0.80). We conclude that the investigator or clinician who wishes to ensure that patients classified as AD are more likely to be AD should choose DSM-III, whereas the investigator who wishes to include the greatest number of AD cases, seldom assigning a diagnosis of no AD to a true case, should choose NINCDS.

Get full access to this article

View all available purchase options and get full access to this article.

Information & Authors

Information

Published In

Neurology®
Volume 40Number 9September 1990
Pages: 1364
PubMed: 2392219

Publication History

Published online: September 1, 1990
Published in print: September 1990

Permissions

Request permissions for this article.

Authors

Affiliations & Disclosures

W. A. Kukull, PhD
From the Departments of Epidemiology (Dr. Kukull), Medicine and Health Services (Dr. Larson), and Biostatistics (J.P. Hughes), University of Washington, Seattle, WA the Department of Psychiatry (Dr. Reifler), Bowman Gray School of Medicine of Wake Forest University, Winston-Salem, NC; the Department of Psychiatry and Behavioral Sciences (Dr. Lampe), University of Washington, Seattle, and American Lake VAMC, Tacoma, WA and the Department of Neurology (Dr. Yerby), Chegan Comprehensive Epilepsy Program, Good Samaritan Hospital and Medical Center, Portland, OR.
E. B. Larson, MD, MPH
From the Departments of Epidemiology (Dr. Kukull), Medicine and Health Services (Dr. Larson), and Biostatistics (J.P. Hughes), University of Washington, Seattle, WA the Department of Psychiatry (Dr. Reifler), Bowman Gray School of Medicine of Wake Forest University, Winston-Salem, NC; the Department of Psychiatry and Behavioral Sciences (Dr. Lampe), University of Washington, Seattle, and American Lake VAMC, Tacoma, WA and the Department of Neurology (Dr. Yerby), Chegan Comprehensive Epilepsy Program, Good Samaritan Hospital and Medical Center, Portland, OR.
B. V. Reifler, MD, MPH
From the Departments of Epidemiology (Dr. Kukull), Medicine and Health Services (Dr. Larson), and Biostatistics (J.P. Hughes), University of Washington, Seattle, WA the Department of Psychiatry (Dr. Reifler), Bowman Gray School of Medicine of Wake Forest University, Winston-Salem, NC; the Department of Psychiatry and Behavioral Sciences (Dr. Lampe), University of Washington, Seattle, and American Lake VAMC, Tacoma, WA and the Department of Neurology (Dr. Yerby), Chegan Comprehensive Epilepsy Program, Good Samaritan Hospital and Medical Center, Portland, OR.
T. H. Lampe, MD
From the Departments of Epidemiology (Dr. Kukull), Medicine and Health Services (Dr. Larson), and Biostatistics (J.P. Hughes), University of Washington, Seattle, WA the Department of Psychiatry (Dr. Reifler), Bowman Gray School of Medicine of Wake Forest University, Winston-Salem, NC; the Department of Psychiatry and Behavioral Sciences (Dr. Lampe), University of Washington, Seattle, and American Lake VAMC, Tacoma, WA and the Department of Neurology (Dr. Yerby), Chegan Comprehensive Epilepsy Program, Good Samaritan Hospital and Medical Center, Portland, OR.
M. S. Yerby, MD, MPH
From the Departments of Epidemiology (Dr. Kukull), Medicine and Health Services (Dr. Larson), and Biostatistics (J.P. Hughes), University of Washington, Seattle, WA the Department of Psychiatry (Dr. Reifler), Bowman Gray School of Medicine of Wake Forest University, Winston-Salem, NC; the Department of Psychiatry and Behavioral Sciences (Dr. Lampe), University of Washington, Seattle, and American Lake VAMC, Tacoma, WA and the Department of Neurology (Dr. Yerby), Chegan Comprehensive Epilepsy Program, Good Samaritan Hospital and Medical Center, Portland, OR.
J. P. Hughes, MS
From the Departments of Epidemiology (Dr. Kukull), Medicine and Health Services (Dr. Larson), and Biostatistics (J.P. Hughes), University of Washington, Seattle, WA the Department of Psychiatry (Dr. Reifler), Bowman Gray School of Medicine of Wake Forest University, Winston-Salem, NC; the Department of Psychiatry and Behavioral Sciences (Dr. Lampe), University of Washington, Seattle, and American Lake VAMC, Tacoma, WA and the Department of Neurology (Dr. Yerby), Chegan Comprehensive Epilepsy Program, Good Samaritan Hospital and Medical Center, Portland, OR.

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Utility of Blood-Based Tau Biomarkers for Mild Cognitive Impairment and Alzheimer’s Disease: Systematic Review and Meta-Analysis, Cells, 12, 8, (1184), (2023).https://doi.org/10.3390/cells12081184
    Crossref
  2. Sensitivity and specificity of neuroimaging for the diagnosis of Alzheimer's disease, Dialogues in Clinical Neuroscience, 5, 1, (89-99), (2022).https://doi.org/10.1080/19585969.2022.12130515
    Crossref
  3. Traumatic Brain Injury and Early Onset Dementia in Post 9-11 Veterans, Brain Injury, 36, 5, (620-627), (2022).https://doi.org/10.1080/02699052.2022.2033846
    Crossref
  4. COllaborative Neuropathology NEtwork Characterizing ouTcomes of TBI (CONNECT-TBI), Acta Neuropathologica Communications, 9, 1, (2021).https://doi.org/10.1186/s40478-021-01122-9
    Crossref
  5. New Perspectives, Neurocritical Care for Neurosurgeons, (697-719), (2021).https://doi.org/10.1007/978-3-030-66572-2_39
    Crossref
  6. Cerebral Microvascular Injury: A Potentially Treatable Endophenotype of Traumatic Brain Injury-Induced Neurodegeneration, Neuron, 103, 3, (367-379), (2019).https://doi.org/10.1016/j.neuron.2019.06.002
    Crossref
  7. Validity of current clinical criteria for Alzheimer's disease, vascular dementia and dementia with Lewy bodies, British Journal of Psychiatry, 174, 1, (45-50), (2018).https://doi.org/10.1192/bjp.174.1.45
    Crossref
  8. The Clinical Diagnosis and Misdiagnosis of Senile Dementia of Lewy Body Type (SDLT), British Journal of Psychiatry, 165, 3, (324-332), (2018).https://doi.org/10.1192/bjp.165.3.324
    Crossref
  9. What should we tell people about dementia?, Advances in Psychiatric Treatment, 9, 5, (335-341), (2018).https://doi.org/10.1192/apt.9.5.335
    Crossref
  10. Cognitive Function Monitoring, Neuromonitoring Techniques, (281-298), (2018).https://doi.org/10.1016/B978-0-12-809915-5.00010-3
    Crossref
  11. See more
Loading...

View Options

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Full Text

View Full Text

Media

Figures

Other

Tables

Share

Share

Share article link

Share